Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Scientists Uncover Why Breast Cancer Becomes Deadlier As We Age (opens in a new tab)

scitechdaily.com · 2026-10-30

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 1 supported
  • 6 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

The one claim we could check holds up. One of seven claims matches the study. This overall rating is based only on the claims we could check. Six claims the study doesn't address.

  • 1 supported
  • 6 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not coveredIn older mice, breast cancer was far more likely to spread to the lungs even when the original tumors grew at roughly the same rate as those in younger animals.View evidenceHide evidence

As statedfar more likely

Why this verdict

The abstract supports the core point that aging markedly increased breast cancer metastasis in multiple mouse models. However, the profile does not specify lung metastasis, does not report that primary tumors grew at roughly the same rate, and gives no quantitative basis for the story’s 'far more likely' framing beyond 'markedly.' Those details are not verifiable from the abstract-level evidence supplied.

1

Study evidence

Aging markedly increases breast cancer metastasis in multiple mouse models, and this pro-metastatic effect requires host expression of RAGE.

“we show that aging markedly increases breast cancer metastasis in multiple mouse models, and this effect is dependent on host expression of the Receptor for Advanced Glycation End-products (RAGE).”
Claim 2 of 7Not coveredResearchers identified the inflammation-related receptor RAGE as playing a central role in the age-related increase in metastasis, and genetically removing RAGE almost completely eliminated the increased spread of cancer in older mice.View evidenceHide evidence

As statedalmost completely eliminated

Why this verdict

The abstract supports a causal role for host RAGE in the age-related metastasis effect, stating that the effect is dependent on host RAGE expression. But it does not specify that RAGE was genetically removed, nor does it provide the magnitude claim that removal 'almost completely eliminated' the increased spread. Those specific method and magnitude details are not verifiable at abstract depth.

1

Study evidence

Aging markedly increases breast cancer metastasis in multiple mouse models, and this pro-metastatic effect requires host expression of RAGE.

“we show that aging markedly increases breast cancer metastasis in multiple mouse models, and this effect is dependent on host expression of the Receptor for Advanced Glycation End-products (RAGE).”
Claim 3 of 7Not coveredThe study found that aging increased levels of molecules that activate RAGE, including S100 and HMGB1, and that this inflammatory activity helped cancer cells invade surrounding tissues and spread.View evidenceHide evidence

Why this verdict

The abstract supports aging-related increases in tumor RAGE ligands and RAGE-dependent inflammatory/metastasis-promoting programs, and it reports that circulating cytokines and S100A8/9 from aged hosts promoted tumor cell invasion in vitro. However, the supplied profile names S100A8/9 and AGEs, not HMGB1, and it does not provide enough detail to verify the story’s specific ligand list or the full causal chain as worded from inflammatory activity to surrounding-tissue invasion and spread.

1

Study evidence

Aging increased tumor RAGE ligand levels, including S100A8/9 and advanced glycation end-products (AGEs), in tumor-bearing mice (abstract).

“Aging increased tumor RAGE ligand levels, including S100A8/9 and AGEs, and induced RAGE-dependent changes in inflammatory, EMT, angiogenic, and extracellular matrix gene programs in tumors.”
2

Study evidence

Circulating cytokines and S100A8/9 from aged hosts promoted tumor cell invasion in vitro, and this invasion was suppressed by inhibition of RAGE or S100A8/9.

“Circulating cytokines and S100A8/9 from aged hosts promoted tumor cell invasion, which was suppressed by RAGE or S100A8/9 inhibition.”
Claim 4 of 7Not coveredAn analysis of breast cancer data from more than 1,000 patients showed that higher expression of AGER, along with elevated activity in related inflammatory genes, was associated with poorer outcomes, but the article says these associations do not prove RAGE causes metastasis in patients.View evidenceHide evidence

As statedmore than 1,000 patients

Why this verdict

The abstract supports the main associational finding: elevated AGER expression and aging-/RAGE-associated transcriptional signatures correlated with poorer survival in human breast cancers, especially in older patients, and causality is not established. However, the abstract-level profile does not provide the claimed sample size of more than 1,000 patients or dataset details, so the claim as stated is not fully verifiable at this depth.

1

Study evidence

Elevated AGER expression and enrichment of aging- and RAGE-associated transcriptional signatures correlated with poorer survival in human breast cancers, with stronger associations reported in older patients.

“In human breast cancers, elevated AGER expression and enrichment of aging- and RAGE-associated transcriptional signatures correlated with poorer survival, especially in older patients.”
Claim 5 of 7Not coveredEarlier research from the same team reportedly showed that the RAGE inhibitor TTP488 (azeliragon) could suppress breast cancer metastasis in preclinical models, and the latest experiments found the drug also reduced invasiveness of cancer cells exposed to serum from aged mice.View evidenceHide evidence

Why this verdict

The abstract supports that RAGE or S100A8/9 inhibition suppressed invasion promoted by aged-host circulating factors. It does not mention TTP488/azeliragon, earlier work from the same team, preclinical suppression of metastasis by that drug, or the exact serum-exposure experiment as framed. These drug-specific and prior-study details are not verifiable from the supplied abstract-level profile.

1

Study evidence

Circulating cytokines and S100A8/9 from aged hosts promoted tumor cell invasion in vitro, and this invasion was suppressed by inhibition of RAGE or S100A8/9.

“Circulating cytokines and S100A8/9 from aged hosts promoted tumor cell invasion, which was suppressed by RAGE or S100A8/9 inhibition.”
Claim 6 of 7Not coveredA clinical study at Georgetown Lombardi is evaluating TTP488 in breast cancer patients undergoing chemotherapy, with attention to safety and cognitive outcomes, but its ability to prevent metastasis in patients remains unproven.View evidenceHide evidence

Why this verdict

The supplied paper profile contains no abstract-level evidence about a Georgetown Lombardi clinical study of TTP488 in patients undergoing chemotherapy, safety, cognitive outcomes, or clinical metastasis prevention. The story’s caveat that patient metastasis prevention remains unproven is directionally consistent with the lack of clinical efficacy evidence here, but the clinical-study claim itself is not verifiable from this profile.

Claim 7 of 7SupportedScientists have uncovered a biological mechanism that may help explain why breast cancer becomes more dangerous with age.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a hedged headline claim that aging-related biology may help explain more dangerous breast cancer: it reports that aging markedly increases metastasis in mouse models, that this effect depends on host RAGE expression, and that human AGER/RAGE-associated signatures correlate with poorer survival. The headline is speculative rather than definitive, so it does not outrun the abstract evidence.

1

Study evidence

Aging markedly increases breast cancer metastasis in multiple mouse models, and this pro-metastatic effect requires host expression of RAGE.

“we show that aging markedly increases breast cancer metastasis in multiple mouse models, and this effect is dependent on host expression of the Receptor for Advanced Glycation End-products (RAGE).”
2

Study evidence

Elevated AGER expression and enrichment of aging- and RAGE-associated transcriptional signatures correlated with poorer survival in human breast cancers, with stronger associations reported in older patients.

“In human breast cancers, elevated AGER expression and enrichment of aging- and RAGE-associated transcriptional signatures correlated with poorer survival, especially in older patients.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • For the human dataset analysis, the abstract does not identify cohorts, sample sizes, survival endpoints, modelling covariates, confounder adjustment, age cutoffs, or independent validation.

    The story notes non-causality but does not mention these additional observational-analysis limitations, which affect how strongly the human survival correlations can be interpreted.

    From Secondary analysis of human tumor gene-expression datasets

6 things the story did carry across
  • Aging markedly increases breast cancer metastasis in multiple mouse models, and the pro-metastatic effect depends on host/microenvironmental RAGE expression.
  • Aged hosts show increased tumor RAGE ligands and RAGE-dependent tumor transcriptional programs, including inflammatory, EMT, angiogenic, and extracellular-matrix programs.
  • Circulating factors from aged hosts, including cytokines and S100A8/9, promote tumor cell invasion in vitro, and RAGE or S100A8/9 inhibition suppresses this invasion.
  • Human breast cancer dataset analyses found higher AGER expression and aging-/RAGE-associated transcriptional signatures correlated with poorer survival, especially in older patients.
  • The human evidence is observational and does not establish that RAGE causes metastasis or poorer outcomes in patients.
  • The abstract suggests RAGE as a potential therapeutic target but provides no clinical evidence that a RAGE inhibitor prevents metastasis in patients.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalAging increases breast cancer metastasis in mice, and this pro-metastatic effect is dependent on host (microenvironmental) RAGE expression.In vivo mouse metastasis assays comparing young versus aged hosts with host-level testing of RAGE requirementExpand

In plain English

In multiple mouse models, aging markedly increases breast cancer metastasis, and this pro‑metastatic effect requires host (microenvironmental) expression of the Receptor for Advanced Glycation End-products (RAGE). Aging was associated with increased tumor RAGE ligands (S100A8/9 and AGEs) and with aged-host circulating factors that promote tumor cell invasion; inhibition of RAGE or S100A8/9 suppressed these invasion-promoting effects.

Key findings

  • Aging markedly increases breast cancer metastasis in multiple mouse models, and this pro-metastatic effect requires host expression of RAGE.
“we show that aging markedly increases breast cancer metastasis in multiple mouse models, and this effect is dependent on host expression of the Receptor for Advanced Glycation End-products (RAGE).”
What this piece can’t prove

2 further details could not be confirmed from the summary.

2in vivo animalAged hosts have increased tumor RAGE ligands (e.g., S100A8/9, AGEs) and show RAGE-dependent tumor transcriptional reprogramming (inflammatory, EMT, angiogenic, ECM programs) consistent with metastatic promotion.in vivo animalExpand

In plain English

In mouse tumor models, aging was reported to increase tumor levels of RAGE ligands (specifically S100A8/9 and advanced glycation end-products) and to induce tumor transcriptional reprogramming—inflammatory, EMT, angiogenic, and extracellular-matrix programs—that the abstract states was dependent on host RAGE expression.

Key findings

  • Aging increased tumor RAGE ligand levels, including S100A8/9 and advanced glycation end-products (AGEs), in tumor-bearing mice (abstract).
  • Aging induced RAGE-dependent changes in tumor gene-expression programs, affecting inflammatory, epithelial–mesenchymal transition (EMT), angiogenic, and extracellular matrix pathways (abstract).
“Aging increased tumor RAGE ligand levels, including S100A8/9 and AGEs, and induced RAGE-dependent changes in inflammatory, EMT, angiogenic, and extracellular matrix gene programs in tumors.”
What this piece can’t prove
  • The abstract does not specify the assays used for ligand quantification, the transcriptomic platform, sample sizes, or how host RAGE dependence was tested (e.g., knockout vs inhibition).

2 further details could not be confirmed from the summary.

3in vitroCirculating factors from aged hosts (cytokines and S100A8/9) promote tumor cell invasion in vitro, and invasion is suppressed by RAGE or S100A8/9 inhibition.in vitro invasion assay (circulating factors, inhibition)Expand

In plain English

The abstract reports that circulating factors from aged hosts — specifically cytokines and the RAGE ligand S100A8/9 — promoted tumor cell invasion in in vitro assays, and that this invasion was reduced when RAGE or S100A8/9 were inhibited.

Key findings

  • Circulating cytokines and S100A8/9 from aged hosts promoted tumor cell invasion in vitro, and this invasion was suppressed by inhibition of RAGE or S100A8/9.
“Circulating cytokines and S100A8/9 from aged hosts promoted tumor cell invasion, which was suppressed by RAGE or S100A8/9 inhibition.”
What this piece can’t prove
  • Abstract does not report numerical results, sample sizes, or reproducibility measures for the invasion assays.
  • Unclear whether findings were replicated across multiple tumor cell lines or species/strains of host animals.

1 further detail could not be confirmed from the summary.

4secondary dataIn human breast cancer datasets, higher AGER expression and aging-/RAGE-associated transcriptional signatures correlate with poorer survival, especially in older patients.Secondary analysis of human tumor gene-expression datasetsExpand

In plain English

Secondary analysis of human breast cancer gene-expression datasets reported that higher tumor AGER expression and enrichment of aging- and RAGE-associated transcriptional signatures were associated with poorer survival, with the association described as stronger in older patients. The abstract does not provide cohort identifiers, sample sizes, effect estimates, survival endpoint details, or modelling covariates.

Key findings

  • Elevated AGER expression and enrichment of aging- and RAGE-associated transcriptional signatures correlated with poorer survival in human breast cancers, with stronger associations reported in older patients.
“In human breast cancers, elevated AGER expression and enrichment of aging- and RAGE-associated transcriptional signatures correlated with poorer survival, especially in older patients.”
What this piece can’t prove
  • Unclear whether associations were adjusted for relevant clinical confounders (e.g., stage, subtype, treatment) or validated in independent cohorts.
  • Observational associations do not establish RAGE as a causal driver of poorer survival without additional evidence.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 37 candidate papers

And 31 more candidates considered.